Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ANIX |
---|---|---|
09:38 ET | 1100 | 2.4559 |
09:43 ET | 500 | 2.47 |
09:59 ET | 100 | 2.4681 |
10:01 ET | 3704 | 2.53 |
10:03 ET | 6228 | 2.53 |
10:19 ET | 500 | 2.485 |
10:48 ET | 1050 | 2.4837 |
10:53 ET | 100 | 2.47 |
10:55 ET | 100 | 2.48 |
11:04 ET | 100 | 2.47 |
11:08 ET | 200 | 2.48 |
11:09 ET | 900 | 2.48 |
11:11 ET | 3000 | 2.47 |
11:22 ET | 505 | 2.46 |
11:33 ET | 226 | 2.46 |
11:36 ET | 100 | 2.4502 |
11:40 ET | 465 | 2.4415 |
11:56 ET | 2200 | 2.45 |
12:05 ET | 100 | 2.435 |
12:09 ET | 1187 | 2.4302 |
12:20 ET | 1000 | 2.4481 |
12:39 ET | 200 | 2.4399 |
12:45 ET | 2486 | 2.455 |
12:52 ET | 289 | 2.4401 |
01:24 ET | 1000 | 2.4685 |
01:39 ET | 1186 | 2.47 |
01:46 ET | 400 | 2.4501 |
02:08 ET | 100 | 2.4899 |
02:13 ET | 1132 | 2.49 |
02:15 ET | 100 | 2.49 |
02:26 ET | 300 | 2.48 |
02:31 ET | 300 | 2.49 |
02:36 ET | 12900 | 2.5201 |
02:40 ET | 300 | 2.538 |
02:42 ET | 532 | 2.535 |
02:44 ET | 200 | 2.55 |
02:45 ET | 400 | 2.5617 |
02:49 ET | 2899 | 2.59 |
02:51 ET | 130 | 2.56 |
02:54 ET | 300 | 2.565 |
02:58 ET | 100 | 2.575 |
03:05 ET | 100 | 2.55 |
03:21 ET | 805 | 2.564 |
03:23 ET | 350 | 2.555 |
03:25 ET | 249 | 2.56 |
03:50 ET | 100 | 2.54 |
03:52 ET | 618 | 2.568 |
03:59 ET | 5962 | 2.57 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Anixa Biosciences Inc | 77.5M | -7.4x | --- |
IO Biotech Inc | 77.7M | -0.7x | --- |
Cognition Therapeutics Inc | 78.1M | -2.2x | --- |
Serina Therapeutics Inc | 79.2M | -0.7x | --- |
Entera Bio Ltd | 80.5M | -8.1x | --- |
Elicio Therapeutics Inc | 81.1M | -1.2x | --- |
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $77.5M |
---|---|
Revenue (TTM) | $210.0K |
Shares Outstanding | 31.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.85 |
EPS | $-0.35 |
Book Value | $0.78 |
P/E Ratio | -7.4x |
Price/Sales (TTM) | 369.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,744.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.